If your skin's stopped bouncing back the way it used to, or you catch every single cold going around the office and take twice as long to shake it (relatable, unfortunately), you've probably fallen down a longevity-peptide rabbit hole at some point looking for an explanation. Cartalax comes up a lot in those searches. But the research behind it is thinner than almost anything else on this site, and you deserve to know that before you get attached to it.
What it actually is
Cartalax is a tiny lab-made peptide, just three amino acids long (alanine, glutamic acid, and aspartic acid, hence the shorthand AED). It's not a hormone and it's not a growth factor. It came out of a single research group in St. Petersburg that's spent decades studying whether short peptides like this one can change how aging cells behave.
That same lab has studied a whole family of these look-alike tripeptides, and if you've already got Cartalax and GHK-Cu confused in your notes app, welcome to the club. It happens to basically everyone who's gone peptide-shopping past midnight. They are not the same thing. GHK-Cu binds copper and has a much bigger, independently confirmed body of research behind it. Cartalax is its own, much thinner story, so don't let the borrowed reputation follow it over.
Why you're paying attention
The interest usually comes from two places. First is your skin. One of the lab studies looked at aging skin cells and measured whether Cartalax changed how fast they grew, died off, and broke down the collagen holding everything together. If you've caught yourself staring at a new line and thinking "that wasn't there last year," that's the exact question this research is asking, even if it's asking it in a dish and not on your actual face.
Second is your immune system, and specifically your thymus, the gland that quietly shrinks as you age and is a big part of why you catch everything now and take twice as long to shake it (the group chat has heard about this one already, we know). One of the Cartalax studies used aging immune cells from that exact gland to see whether the peptide changed how they grew and survived. It's a real question, even if you've never once said the word thymus out loud before this paragraph.
What the research actually shows
Across several of these lab studies, Cartalax showed up doing something consistent, which is more than you can say for most trending peptides. In stem cells, it nudged genes tied to aging and stress response. In skin cells, it changed how fast cells grew and how quickly they died off. In kidney cells from old rats, it affected proteins linked to cellular aging. In thymus cells, it changed how those immune cells grew and survived.
The findings line up with each other across the board, which is genuinely a good sign. The catch is that every one of these studies came from the same lab, using the same general method of adding the peptide to cells in a dish and watching what happens. A finding no outside lab has ever repeated is a lead, not a settled fact, and nobody outside that one research group has repeated this.
The honest part
A few things worth knowing before you get too attached to this one.
Everything known about Cartalax comes from cells in a dish (what scientists call in vitro work). No animal studies. No human trials. Nobody has tested this in a living body of any kind, mouse or otherwise, and published what happened.
That doesn't make the questions pointless, and the cell-level findings are genuinely interesting. But there's a real gap between "this changed something in a petri dish" and "this would do something for you," and right now nobody's done the work to close it. Given how little outside interest this compound has gotten, that work might not be coming anytime soon either.
If you're comparing options for skin or longevity, there are others with a lot more evidence behind them. GHK-Cu alone has hundreds of studies. Epithalon, from the same Russian research tradition, at least has a wider spread of studies, even if it's still concentrated in that same lab. Cartalax is one of the more speculative picks on this whole list, and it's fair to treat it that way, no matter how good it sounds in a longevity forum thread at 1am.